Financings in Brief: Beckman Instruments
This article was originally published in The Gray Sheet
Beckman Instruments: Issues $100 mil. in debentures due June 1, 2026 at an interest rate of 7.05%. Proceeds will be used to fund "general corporate purposes and to repay the company's existing commercial paper borrowings," Beckman says. Beckman filed a registration statement with the Securities and Exchange Commission in April for issuance of up to $200 mil. in debt securities. The company says it "currently has no plans to issue the remaining $100 mil." covered by the SEC filing...
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.